Lung cancer tumorigenicity and drug resistance are enhanced through ALDHNhiCD44hi tumor initiating cells

Jing Liu, Zhijie Xiao, Sunny Kit Man Wong, Vicky Pui Chi Tin, Ka Yan Ho, Junwen Wang, Mai Har Sham, Maria Pik Wong

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Limited improvement in long term survival of lung cancer patients has been achieved by conventional chemotherapy or targeted therapy. To explore the potentials of tumor initiating cells (TIC)-directed therapy, it is essential to identify the cell targets and understand their maintenance mechanisms. We have analyzed the performance of ALDH/CD44 co-expression as TIC markers and treatment targets of lung cancer using well-validated in vitro and in vivo analyses in multiple established and patient-derived lung cancer cells. The ALDHhiCD44hi subset showed the highest enhancement of stem cell phenotypic properties compared to ALDHhiCD44lo, ALDHloCD44hi, ALDHloCD44lo cells and unsorted controls. They showed higher invasion capacities, pluripotency genes and epithelial-mesenchymal transition transcription factors expression, lower intercellular adhesion protein expression and higher G2/M phase cell cycle fraction. In immunosuppressed mice, the ALDHhiCD44hi xenografts showed the highest tumor induction frequency, serial transplantability, shortest latency, largest volume and highest growth rates. Inhibition of sonic Hedgehog and Notch developmental pathways reduced ALDH+CD44+ compartment. Chemotherapy and targeted therapy resulted in higher ALDHhiCD44hi subset viability and ALDHloCD44lo subset apoptosis fraction. ALDH inhibition and CD44 knockdown led to reduced stemness gene expression and sensitization to drug treatment. In accordance, clinical lung cancers containing a higher abundance of ALDH and CD44-coexpressing cells was associated with lower recurrence-free survival. Together, results suggested the ALDHhiCD44hi compartment was the cellular mediator of tumorigenicity and drug resistance. Further investigation of the regulatory mechanisms underlying ALDHhiCD44hi TIC maintenance would be beneficial for the development of long term lung cancer control.

Original languageEnglish (US)
Pages (from-to)1686-1699
Number of pages14
JournalOncotarget
Volume4
Issue number10
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Drug Resistance
Lung Neoplasms
Maintenance
Drug Therapy
Epithelial-Mesenchymal Transition
Survival
Hedgehogs
G2 Phase
Therapeutics
Cell- and Tissue-Based Therapy
Heterografts
Cell Division
Cell Cycle
Transcription Factors
Stem Cells
Apoptosis
Gene Expression
Recurrence
Growth

Keywords

  • Aldehyde dehydrogenase
  • CD44
  • Drug resistance
  • lung cancer
  • Tumor initiating cell

ASJC Scopus subject areas

  • Oncology

Cite this

Liu, J., Xiao, Z., Wong, S. K. M., Tin, V. P. C., Ho, K. Y., Wang, J., ... Wong, M. P. (2013). Lung cancer tumorigenicity and drug resistance are enhanced through ALDHNhiCD44hi tumor initiating cells. Oncotarget, 4(10), 1686-1699.

Lung cancer tumorigenicity and drug resistance are enhanced through ALDHNhiCD44hi tumor initiating cells. / Liu, Jing; Xiao, Zhijie; Wong, Sunny Kit Man; Tin, Vicky Pui Chi; Ho, Ka Yan; Wang, Junwen; Sham, Mai Har; Wong, Maria Pik.

In: Oncotarget, Vol. 4, No. 10, 10.2013, p. 1686-1699.

Research output: Contribution to journalArticle

Liu, J, Xiao, Z, Wong, SKM, Tin, VPC, Ho, KY, Wang, J, Sham, MH & Wong, MP 2013, 'Lung cancer tumorigenicity and drug resistance are enhanced through ALDHNhiCD44hi tumor initiating cells', Oncotarget, vol. 4, no. 10, pp. 1686-1699.
Liu, Jing ; Xiao, Zhijie ; Wong, Sunny Kit Man ; Tin, Vicky Pui Chi ; Ho, Ka Yan ; Wang, Junwen ; Sham, Mai Har ; Wong, Maria Pik. / Lung cancer tumorigenicity and drug resistance are enhanced through ALDHNhiCD44hi tumor initiating cells. In: Oncotarget. 2013 ; Vol. 4, No. 10. pp. 1686-1699.
@article{5f9d71ae56724141b7fd7b35ec322569,
title = "Lung cancer tumorigenicity and drug resistance are enhanced through ALDHNhiCD44hi tumor initiating cells",
abstract = "Limited improvement in long term survival of lung cancer patients has been achieved by conventional chemotherapy or targeted therapy. To explore the potentials of tumor initiating cells (TIC)-directed therapy, it is essential to identify the cell targets and understand their maintenance mechanisms. We have analyzed the performance of ALDH/CD44 co-expression as TIC markers and treatment targets of lung cancer using well-validated in vitro and in vivo analyses in multiple established and patient-derived lung cancer cells. The ALDHhiCD44hi subset showed the highest enhancement of stem cell phenotypic properties compared to ALDHhiCD44lo, ALDHloCD44hi, ALDHloCD44lo cells and unsorted controls. They showed higher invasion capacities, pluripotency genes and epithelial-mesenchymal transition transcription factors expression, lower intercellular adhesion protein expression and higher G2/M phase cell cycle fraction. In immunosuppressed mice, the ALDHhiCD44hi xenografts showed the highest tumor induction frequency, serial transplantability, shortest latency, largest volume and highest growth rates. Inhibition of sonic Hedgehog and Notch developmental pathways reduced ALDH+CD44+ compartment. Chemotherapy and targeted therapy resulted in higher ALDHhiCD44hi subset viability and ALDHloCD44lo subset apoptosis fraction. ALDH inhibition and CD44 knockdown led to reduced stemness gene expression and sensitization to drug treatment. In accordance, clinical lung cancers containing a higher abundance of ALDH and CD44-coexpressing cells was associated with lower recurrence-free survival. Together, results suggested the ALDHhiCD44hi compartment was the cellular mediator of tumorigenicity and drug resistance. Further investigation of the regulatory mechanisms underlying ALDHhiCD44hi TIC maintenance would be beneficial for the development of long term lung cancer control.",
keywords = "Aldehyde dehydrogenase, CD44, Drug resistance, lung cancer, Tumor initiating cell",
author = "Jing Liu and Zhijie Xiao and Wong, {Sunny Kit Man} and Tin, {Vicky Pui Chi} and Ho, {Ka Yan} and Junwen Wang and Sham, {Mai Har} and Wong, {Maria Pik}",
year = "2013",
month = "10",
language = "English (US)",
volume = "4",
pages = "1686--1699",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "10",

}

TY - JOUR

T1 - Lung cancer tumorigenicity and drug resistance are enhanced through ALDHNhiCD44hi tumor initiating cells

AU - Liu, Jing

AU - Xiao, Zhijie

AU - Wong, Sunny Kit Man

AU - Tin, Vicky Pui Chi

AU - Ho, Ka Yan

AU - Wang, Junwen

AU - Sham, Mai Har

AU - Wong, Maria Pik

PY - 2013/10

Y1 - 2013/10

N2 - Limited improvement in long term survival of lung cancer patients has been achieved by conventional chemotherapy or targeted therapy. To explore the potentials of tumor initiating cells (TIC)-directed therapy, it is essential to identify the cell targets and understand their maintenance mechanisms. We have analyzed the performance of ALDH/CD44 co-expression as TIC markers and treatment targets of lung cancer using well-validated in vitro and in vivo analyses in multiple established and patient-derived lung cancer cells. The ALDHhiCD44hi subset showed the highest enhancement of stem cell phenotypic properties compared to ALDHhiCD44lo, ALDHloCD44hi, ALDHloCD44lo cells and unsorted controls. They showed higher invasion capacities, pluripotency genes and epithelial-mesenchymal transition transcription factors expression, lower intercellular adhesion protein expression and higher G2/M phase cell cycle fraction. In immunosuppressed mice, the ALDHhiCD44hi xenografts showed the highest tumor induction frequency, serial transplantability, shortest latency, largest volume and highest growth rates. Inhibition of sonic Hedgehog and Notch developmental pathways reduced ALDH+CD44+ compartment. Chemotherapy and targeted therapy resulted in higher ALDHhiCD44hi subset viability and ALDHloCD44lo subset apoptosis fraction. ALDH inhibition and CD44 knockdown led to reduced stemness gene expression and sensitization to drug treatment. In accordance, clinical lung cancers containing a higher abundance of ALDH and CD44-coexpressing cells was associated with lower recurrence-free survival. Together, results suggested the ALDHhiCD44hi compartment was the cellular mediator of tumorigenicity and drug resistance. Further investigation of the regulatory mechanisms underlying ALDHhiCD44hi TIC maintenance would be beneficial for the development of long term lung cancer control.

AB - Limited improvement in long term survival of lung cancer patients has been achieved by conventional chemotherapy or targeted therapy. To explore the potentials of tumor initiating cells (TIC)-directed therapy, it is essential to identify the cell targets and understand their maintenance mechanisms. We have analyzed the performance of ALDH/CD44 co-expression as TIC markers and treatment targets of lung cancer using well-validated in vitro and in vivo analyses in multiple established and patient-derived lung cancer cells. The ALDHhiCD44hi subset showed the highest enhancement of stem cell phenotypic properties compared to ALDHhiCD44lo, ALDHloCD44hi, ALDHloCD44lo cells and unsorted controls. They showed higher invasion capacities, pluripotency genes and epithelial-mesenchymal transition transcription factors expression, lower intercellular adhesion protein expression and higher G2/M phase cell cycle fraction. In immunosuppressed mice, the ALDHhiCD44hi xenografts showed the highest tumor induction frequency, serial transplantability, shortest latency, largest volume and highest growth rates. Inhibition of sonic Hedgehog and Notch developmental pathways reduced ALDH+CD44+ compartment. Chemotherapy and targeted therapy resulted in higher ALDHhiCD44hi subset viability and ALDHloCD44lo subset apoptosis fraction. ALDH inhibition and CD44 knockdown led to reduced stemness gene expression and sensitization to drug treatment. In accordance, clinical lung cancers containing a higher abundance of ALDH and CD44-coexpressing cells was associated with lower recurrence-free survival. Together, results suggested the ALDHhiCD44hi compartment was the cellular mediator of tumorigenicity and drug resistance. Further investigation of the regulatory mechanisms underlying ALDHhiCD44hi TIC maintenance would be beneficial for the development of long term lung cancer control.

KW - Aldehyde dehydrogenase

KW - CD44

KW - Drug resistance

KW - lung cancer

KW - Tumor initiating cell

UR - http://www.scopus.com/inward/record.url?scp=84886743503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886743503&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 1686

EP - 1699

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -